Trials / NCT04120883
Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO)
Terminated Phase 1 / Phase 2 Drug / neuroprotection
Why it stopped: Unable to recruit additional participants after multiple extensions to planned enrollment period.
- Sponsor
- University of Michigan
- Treatment
- Hydroxychloroquine lower dose; Hydroxychloroquine higher dose
- Gene
- RHO
- Conditions
- Retinitis Pigmentosa
- Ages
- 18 Years to no upper limit
- Enrollment
- 8 participants
- Started
- 2020-02-25
- Main results expected
- 2024-08-05
- Results posted
- Not yet
- Record last updated
- 2024-10-26
What the study is testing
This research study is being done to learn what effect 12 months of treatment with oral hydroxychloroquine (HCQ) will have on the retina in people with retinitis pigmentosa (RP). The hypothesis is that treatment with HCQ is safe and tolerable in patients with autosomal dominant retinitis pigmentosa (adRP) caused by P23H-RHO, and may arrest progression of retinal degeneration by altering the autophagy pathway in photoreceptors.
Participants that meet eligibility and agree to the study will be asked to take the study medication (HCQ) for 12 months and have evaluations for up to approximately 18 months from the baseline visit. There will be a total of 6 visits (1 is a phone visit) and will include general examinations, blood work, electrocardiograms, along with special testing of the retina.
Where it runs
United States (1)
- University of Michigan, Ann Arbor, Michigan